ANG1005 is a Proof-of-Concept of the Platform

- Angiopep-2 + Paclitaxel Covered by Patents on LC Applications until 2036

Novel, targeted, peptide-drug conjugate leverages the LRP-1 pathway to effectively cross the Blood-Brain Barrier to treat lethal Brain Cancer Breast Metastases (BCBM)



B³ Pharma CONFIDENTIAL